Business Wire

CA-HAI-ROBOTICS

22.3.2022 11:44:04 CET | Business Wire | Press release

Share
HAI ROBOTICS to Debut Cutting-edge ACR Systems in U.S. at MODEX 2022

HAI ROBOTICS , the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will present its highly flexible totes-to-person warehouse automation solution at this year’s MODEX 2022 show, Booth C4585 at Georgia World Congress Center in Atlanta from March 28th to 31st.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005613/en/

With its robots being exhibited also by MHS, SVT Robotics, GreyOrange and Tompkins Robotics, the company will demonstrate alongside its strategic partners how its state-of-the-art warehousing technology complements the global supply chain.

Days ahead of MODEX 2022, HAI ROBOTICS announced new partnerships with Tompkins Robotics and Storage Solutions. The partnerships will see technology and solutions developed by HAI ROBOTICS being applied to various industries across North America.

Brian Reinhart, Vice President of Sales and Marketing at HAI ROBOTICS U.S., said the company would have a full display of its commitment to customers, partners and the U.S. market at the show after being in the market for over a year.

"It's a very exciting time for HAI ROBOTICS as we continue our expansion and growth in the U.S." he said. "In order to best serve the market and accommodate the requests of our end users, we are developing a robust, strong, and valuable partner network."

Reinhart, a veteran in the material-handling industry, says: "In a short time, we have planted deep roots in the U.S."

In addition to existing customers and partners, HAI ROBOTICS has established a U.S. HQ in Fremont, CA, a fully functional Demo Center with a decentralized sales and implementation strategy, positioning employees in 15 different states across the country.

The company's "ambitious goals have hiring, onboarding, and training of talented individuals as a top priority." "We want to be where our customers are to best serve them. We are committed to providing our partners with the best industry products, solutions, and service," he said.

Exhibits

The company's exhibits this year include two types of ACR robots and one workstation that were crafted to explore the full potentials of order-fulfillment efficiency, deployment flexibility and scalability in a goods-to-person order-handling context.

The HAIPICK A42T robot to be displayed is an evolution of the company’s IFOY 2021 "Best in Intralogistics" title earner. With a telescopic lift function that can flexibly adjust its picking height, it can handle bins (totes or cartons) at a storage height ranging from 0.28 to 10 meters.

It can carry 8 loads to feed goods-to-person workstations in one move, and shuttle between different storage areas without hindrance.

The HAIPICK A3 fork-lifting robot is a new invention that targets wider warehousing scenarios in addition to bin storage. It handles goods that don’t require a container, such as tires, trays and boards that can be lifted by a fork from the bottom. Its fork-lifting design brings an extra benefit of higher storage density, since spaces between neighboring bins can be reduced. This type of robot is a good match with working environments where control for dust, static and pollution is strict.

In addition to high flexibility, the HAIPICK robots outperform other goods-transporting robots by bringing every inch under the ceiling available for storage. However, it is the teamwork with the HAIPORT-powered Workstation that maximizes a warehouse’s throughput capacity.

A HAIPORT-powered Workstation , which can fulfill orders at in-bound and out-bound, involves collaboration between HAIPICK robots, HAIPORT and conveyor belts. HAIPORT is an automatic loading and unloading machine that can be docked with ACR robots and conveyor belts. At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the entry side of the HAIPORT, then transferred onto the conveyor belts for sorting per system orders and moved to the exit side of the HAIPORT, where they were fetched by robots for the next round of order processing.

The HAIPORT-powered Workstation is suitable for medium-to-large warehouses that have high throughput requirement of at least 400 bins per hour. It's machine rate can deliver 600 bins per hour to an operator. It suits for extensive storage scenarios in which medium and small-sized bins are used, such as raw materials, small electronics, apparel, medicine, retails and 3PL industries that have large number of SKUs.

ABOUT HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye